Relationship between peroxisome proliferator-activated receptor-γ expression and differentiation of human esophageal squamous cell carcinoma

2005 ◽  
Author(s):  
Takashi Takashima ◽  
Yasuhiro Fujiwara ◽  
Masaki Hamaguchi ◽  
Eiji Sasaki ◽  
Kazunari Tominaga ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor

scholarly journals Pparg may Promote Chemosensitivity of Hypopharyngeal Squamous Cell Carcinoma

PPAR Research ◽  
2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Meng Lian ◽  
Jiaming Chen ◽  
Xixi Shen ◽  
Lizhen Hou ◽  
Jugao Fang
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Large Scale ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Regulatory Pathways ◽  
Hypopharyngeal Squamous Cell Carcinoma ◽  
Expression Levels

The upregulation of peroxisome proliferator-activated receptor gamma (PPARG) has been shown to increase the chemosensitivity of several human cancers. This study is aimed at studying if PPARG sensitizes hypopharyngeal squamous cell carcinoma (HSCC) in chemotherapeutic treatments and at dissecting possible mechanisms of observed effects. We integrated large-scale literature data and HSCC gene expression data to identify regulatory pathways that link PPARG and chemosensitivity in HSCC. Expression levels of molecules within the PPARG regulatory pathways were compared in 21 patients that underwent chemotherapy for primary HSCC, including 12 chemotherapy-sensitive patients (CSP) and 9 chemotherapy-nonsensitive patients (CNSP). In the CPS group, expression levels of PPARG were higher than that in the CNSP group (log‐fold‐change=0.50). Structured text mining identified two chemosensitivity-related regulatory pathways driven by PPARG. In the CSP group, expression levels for 7 chemosensitivity-promoting genes were increased, while for 13 chemosensitivity suppressing the gene expression levels were decreased. Our results support the chemosensitivity-promoting role of PPARG in HSCC tumor cells, most likely by affecting both cell proliferation and cell motility pathways.

scholarly journals Critical Role of Peroxisome Proliferator-Activated Receptor γ on Anoikis and Invasion of Squamous Cell Carcinoma

2005 ◽  
Vol 11 (11) ◽  
pp. 4012-4021 ◽  
Author(s):  
Tomotake Masuda ◽  
Koichiro Wada ◽  
Atsushi Nakajima ◽  
Masaya Okura ◽  
Chiho Kudo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Critical Role ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor

scholarly journals Variation of PPARG Expression in Chemotherapy-Sensitive Patients of Hypopharyngeal Squamous Cell Carcinoma

PPAR Research ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Meng Lian ◽  
Yong Tao ◽  
Jiaming Chen ◽  
Xixi Shen ◽  
Lizhen Hou ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tnm Stage ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Hypopharyngeal Squamous Cell Carcinoma ◽  
Significant Gene ◽  
Dataset Analysis ◽  
Pparg Expression

Our previous study showed that the upregulation of peroxisome proliferator-activated receptor gamma (PPARG) could promote chemosensitivity of hypopharyngeal squamous cell carcinoma (HSCC) in chemotherapeutic treatments. Here, we acquired two more independent expression data of PPARG to validate the expression levels of PPARG in chemotherapy-sensitive patients (CSP) and its individualized variations compared to chemotherapy-non-sensitive patients (CNSP). Our results showed that overall PPARG expression was mildly downregulated ( log   fold   change = − 0.55 ; p value = 0.42; overexpression in three CSPs and reduced expression in four CSPs), which was not consistent with previous results ( log   fold   change = 0.50 ; p = 0.22 ; overexpression in nine CSPs and reduced expression in three CSPs). Both studies indicated that PPARG expression variation was significantly associated with the Tumor-Node-Metastasis (TNM) stage ( p = 7.45 e − 7 and 6.50 e − 4 , for the first and second studies, respectively), which was used as one of the predictors of chemosensitivity. The new dataset analysis revealed 51 genes with significant gene expression changes in CSPs ( LFC > 1 or <-1; p value < 0.01), and two of them (TMEM45A and RBP1) demonstrated strong coexpression with PPARG ( Pearson   correlation   coefficient > 0.6 or <-0.6). There were 21 significant genes in the data from the first study, with no significant association with PPARG and no overlap with the 51 genes revealed in this study. Our results support the connection between PPARG and chemosensitivity in HSCC tumor cells. However, significant PPARG variation exists in CSPs, which may be influenced by multiple factors, including the TNM stage.

Sign in / Sign up

Export Citation Format

Share Document